India, June 30 -- INmune Bio Inc. (INMB) Monday said that its Phase 2 MINDFuL study of XPro in patients with early Alzheimers Disease (AD) with biomarkers of inflammation did not meet its primary goal. The company's shares were more than 50% down in pre-market.
The MINDFuL study enrolled participants with early-stage AD to evaluate XPro in slowing cognitive decline by tackling neuroinflammation. Patients with at least one of four inflammatory biomarkers including elevated CRP, ESR, HbA1c, or at least one ApoE4 allele were randomized to receive either XPro or placebo.
The study failed to meet the primary endpoint of change in cognition over 6 months on the Early Mild Alzheimers Cognitive Composite (EMACC), a cognitive assessment designed t...